ZA200805160B - Imidazoles as GABAB receptor modulators - Google Patents
Imidazoles as GABAB receptor modulatorsInfo
- Publication number
- ZA200805160B ZA200805160B ZA200805160A ZA200805160A ZA200805160B ZA 200805160 B ZA200805160 B ZA 200805160B ZA 200805160 A ZA200805160 A ZA 200805160A ZA 200805160 A ZA200805160 A ZA 200805160A ZA 200805160 B ZA200805160 B ZA 200805160B
- Authority
- ZA
- South Africa
- Prior art keywords
- imidazoles
- receptor modulators
- gabab receptor
- gabab
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0502905 | 2005-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200805160B true ZA200805160B (en) | 2009-10-28 |
Family
ID=38188930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200805160A ZA200805160B (en) | 2005-12-23 | 2008-06-12 | Imidazoles as GABAB receptor modulators |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20080312305A1 (no) |
| EP (1) | EP1968946A4 (no) |
| JP (1) | JP2009521429A (no) |
| KR (1) | KR20080090448A (no) |
| CN (1) | CN101341131A (no) |
| AU (1) | AU2006327316A1 (no) |
| BR (1) | BRPI0620373A2 (no) |
| CA (1) | CA2632020A1 (no) |
| IL (1) | IL191767A0 (no) |
| NO (1) | NO20083248L (no) |
| WO (1) | WO2007073299A1 (no) |
| ZA (1) | ZA200805160B (no) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401653D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
| BRPI0620415A2 (pt) * | 2005-12-23 | 2011-11-08 | Astrazeneca Ab | composto e sais farmaceuticamente e farmacologicamente aceitáveis do mesmo, e enantiÈmeros do composto e sais do mesmo, composição farmaceutica, e, uso de um composto opcionalmente em combinação com um agonista do receptor de gabab, e, métodos para o tratamento de doença, de um distúrbio, e de sìndrome |
| CA2631991A1 (en) * | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Heterocyclic gaba-b modulators |
| CN101384558A (zh) * | 2005-12-23 | 2009-03-11 | 阿斯利康(瑞典)有限公司 | Gaba-b受体调节剂 |
| KR20080091452A (ko) * | 2005-12-23 | 2008-10-13 | 아스트라제네카 아베 | 위장 장애의 치료를 위한 이미다졸 유도체 |
| CN107445919A (zh) | 2010-03-12 | 2017-12-08 | 奥默罗斯公司 | Pde10抑制剂以及相关组合物和方法 |
| WO2011113904A1 (en) | 2010-03-17 | 2011-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
| US10653672B2 (en) * | 2014-02-07 | 2020-05-19 | National University Corporation Tokyo Medical And Dental University | Myogenesis promotor, muscle atrophy inhibitor, medical composition and TAZ activator |
| NZ630810A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ630803A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Optically active pde10 inhibitor |
| TW201623257A (zh) | 2014-05-09 | 2016-07-01 | 奧利安公司 | 藥理活性之喹唑啉二酮衍生物 |
| BR112017022936A2 (pt) | 2015-04-24 | 2018-07-17 | Omeros Corp | inibidores da pde10 e composições e métodos relacionados |
| SG11201710694YA (en) | 2015-06-22 | 2018-01-30 | Sumitomo Dainippon Pharma Co Ltd | Bicyclic heterocyclic amide derivative |
| JP6692354B2 (ja) | 2015-06-22 | 2020-05-13 | 大日本住友製薬株式会社 | １，４−ジ置換イミダゾール誘導体 |
| JP2018535969A (ja) | 2015-11-04 | 2018-12-06 | オメロス コーポレーション | Ｐｄｅ１０阻害剤の固体状態形態 |
| JP6896701B2 (ja) | 2016-02-26 | 2021-06-30 | 大日本住友製薬株式会社 | イミダゾリルアミド誘導体 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3876655A (en) * | 1971-08-18 | 1975-04-08 | Beecham Group Ltd | Anti-inflammatory acyl imidazoles |
| US4659720A (en) * | 1982-12-20 | 1987-04-21 | Merck & Co., Inc. | 5-amino or substituted amino imidazoles useful to treat coccidiosis |
| FR2663934B1 (fr) * | 1990-06-27 | 1994-06-03 | Adir | Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent. |
| US5214063A (en) * | 1990-06-27 | 1993-05-25 | Adir Et Compagnie | 4-aminobutyric acid compounds, compositions and methods of use for treating disorders related to a dysfunction of GABAB receptors |
| DE4213750A1 (de) * | 1992-04-25 | 1993-10-28 | Basf Ag | Verfahren zur Herstellung von 3-(Hydroxyphenyl)-propionaldehyden und gegebenenfalls der Herstellung von 3-(hydroxyphenyl)-propanolen |
| SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| AU5859598A (en) * | 1996-12-24 | 1998-07-17 | Novartis Ag | (thio)morpholine-substituted carboxylic and phosphinic acids |
| CN100341862C (zh) * | 2001-09-14 | 2007-10-10 | 三菱制药株式会社 | 噻唑烷衍生物及其医药用途 |
| SE0401653D0 (sv) * | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
| CA2631991A1 (en) * | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Heterocyclic gaba-b modulators |
| KR20080091452A (ko) * | 2005-12-23 | 2008-10-13 | 아스트라제네카 아베 | 위장 장애의 치료를 위한 이미다졸 유도체 |
| CN101384558A (zh) * | 2005-12-23 | 2009-03-11 | 阿斯利康(瑞典)有限公司 | Gaba-b受体调节剂 |
| BRPI0620415A2 (pt) * | 2005-12-23 | 2011-11-08 | Astrazeneca Ab | composto e sais farmaceuticamente e farmacologicamente aceitáveis do mesmo, e enantiÈmeros do composto e sais do mesmo, composição farmaceutica, e, uso de um composto opcionalmente em combinação com um agonista do receptor de gabab, e, métodos para o tratamento de doença, de um distúrbio, e de sìndrome |
| AU2008241604A1 (en) * | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | Xanthine compounds having a positive allosteric GABAB receptor modulator effect |
| US20080262064A1 (en) * | 2007-04-18 | 2008-10-23 | Astrazeneca Ab | Novel Compounds For The Treatment Of GI Disorders 682 |
-
2006
- 2006-12-21 EP EP06824533A patent/EP1968946A4/en not_active Withdrawn
- 2006-12-21 AU AU2006327316A patent/AU2006327316A1/en not_active Abandoned
- 2006-12-21 JP JP2008547166A patent/JP2009521429A/ja active Pending
- 2006-12-21 BR BRPI0620373-6A patent/BRPI0620373A2/pt not_active IP Right Cessation
- 2006-12-21 CN CNA2006800484624A patent/CN101341131A/zh active Pending
- 2006-12-21 WO PCT/SE2006/001463 patent/WO2007073299A1/en active Application Filing
- 2006-12-21 US US12/158,159 patent/US20080312305A1/en not_active Abandoned
- 2006-12-21 KR KR1020087017999A patent/KR20080090448A/ko not_active Application Discontinuation
- 2006-12-21 CA CA002632020A patent/CA2632020A1/en not_active Abandoned
-
2008
- 2008-05-27 IL IL191767A patent/IL191767A0/en unknown
- 2008-06-12 ZA ZA200805160A patent/ZA200805160B/xx unknown
- 2008-07-22 NO NO20083248A patent/NO20083248L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL191767A0 (en) | 2008-12-29 |
| BRPI0620373A2 (pt) | 2011-11-08 |
| JP2009521429A (ja) | 2009-06-04 |
| EP1968946A4 (en) | 2010-05-05 |
| AU2006327316A1 (en) | 2007-06-28 |
| CN101341131A (zh) | 2009-01-07 |
| CA2632020A1 (en) | 2007-06-28 |
| WO2007073299A1 (en) | 2007-06-28 |
| EP1968946A1 (en) | 2008-09-17 |
| US20080312305A1 (en) | 2008-12-18 |
| NO20083248L (no) | 2008-07-23 |
| KR20080090448A (ko) | 2008-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200805160B (en) | Imidazoles as GABAB receptor modulators | |
| SI1928845T1 (sl) | Aminodiazepini kot modulatorji Tollu podobnega receptorja | |
| GB0710845D0 (en) | Communication system | |
| PL2185293T3 (pl) | System aplikowania | |
| EP2214452A4 (en) | COMMUNICATION SYSTEM | |
| ZA200805242B (en) | GABAB receptor modulators | |
| EP2139130A4 (en) | COMMUNICATION SYSTEM | |
| SI2094658T1 (sl) | Spojine tetrahidrociklopenta(b)indola kot modulatorji androgenskega receptorja | |
| EP2148326A4 (en) | COMMUNICATION SYSTEM | |
| GB0721155D0 (en) | Communication system | |
| IL198990A0 (en) | Cb1 receptor modulators | |
| GB0701992D0 (en) | Grehlin Receptor Modulators | |
| GB0716540D0 (en) | Mount | |
| GB0703328D0 (en) | Gel forming compounds | |
| ZA201004828B (en) | Cannabinoid receptor modulators | |
| GB0712221D0 (en) | Communication system | |
| ZA200805241B (en) | Heterocyclic GABAB modulators | |
| IL200801A0 (en) | Pyrimidinyl-piperazines useful as d3/d2 receptor ligands | |
| GB0705264D0 (en) | Gel forming compounds | |
| IL184532A0 (en) | Novel adenosine a3 receptor modulators | |
| ZA200806237B (en) | Cannibinoid receptor modulators | |
| GB0716534D0 (en) | Mount | |
| EP2154795A4 (en) | COMMUNICATION SYSTEM | |
| ZA200904663B (en) | CB1 receptor modulators | |
| EP2204786A4 (en) | COMMUNICATION SYSTEM |